Showing 61–72 of 192 resultsSorted by latest
Pharma & Biotech
The company continues to invest in disruptive innovation while maintaining tight control over costs to ensure long-term competitiveness.
The colocation business remained robust across all three operating regions, while interconnection revenue outpaced colocation growth.
AMGN remains focused on long-term growth while navigating regulatory and political changes, falling net prices, and the loss of exclusivity on certain products.
United Therapeutics (UTHR) has started a three-year plan focused on key clinical and regulatory events.
GILD reported a 6% increase in total revenue for 2024, reaching $28.8 billion, mainly due to strong sales in HIV, Oncology, and Liver Disease, partially offset by lower Veklury sales.
AZN’s revenue grew 25% in Q4 2024, pushing full-year growth to 21%, surpassing forecasts.
Zoetis reported a strong financial year with $9.3 billion in revenue, representing an 8% increase on a reported basis and an 11% operational growth.
In 2024, the GE Healthcare closed 50 enterprise deals, including a $1 billion partnership with Sutter Health, bringing the total large deal value to over $5 billion.
Adjusted for Julian’s impact, growth would have been 9% for Q4 and 7% for the year. Advanced Surgery sales grew 6% due to strong demand for hemostats and sealants.
The rare disease segment grew strongly, bringing in $535 million in Q4 revenue, up 13%. SKYCLARYS performed well, with revenue jumping 83% to $102 million as more patients started treatment.
Pfizer successfully integrated the Seagen business, one of its largest investments in the past decade, strengthening its position as a leading oncology company. The company earned the top spot in the 2024 IQVIA US Field Force Ranking and ranked first or second in 70% of its key specialties.
Merck continues advancing its pipeline with strong research and regulatory progress. WINREVAIR’s Phase 3 ZENITH trial for high-risk pulmonary arterial hypertension (PAH) showed excellent results, leading to an early trial stop.